ATN1-targeted antisense oligonucleotide

· n-Lorem Foundation

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ATN1-targeted antisense oligonucleotide, covering 2025-07-24 to 2025-07-24. Get the full timeline:

Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation [Phase 1, Phase 2]